Effect of multimerization on membrane association of rous sarcoma virus and HIV-1 matrix domain proteins

Journal of Virology

Volumn 87, Issue 24, 2013, Pages 13598-13608

  Dick, Robert A ^a   Kamynina, Elena ^a   Vogt, Volker M ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FK 506 BINDING PROTEIN; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS 1 MATRIX DOMAIN PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LIPOSOME; RIBONUCLEASE; RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIMERIZATION; DNA VECTOR; FIBROBLAST; FLOTATION; FLUORESCENCE IMAGING; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; IONIC STRENGTH; LIPID COMPOSITION; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN MULTIMERIZATION; PROTEIN PURIFICATION; QUAIL; ROUS SARCOMA ONCOVIRUS; SUCROSE GRADIENT;

ANIMALS; CELL LINE; CELL MEMBRANE; CYTOPLASM; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; QUAIL; ROUS SARCOMA VIRUS; SARCOMA, AVIAN;

EID: 84888052254     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01659-13     Document Type: Article

References (92)

1. Murray P, Li Z, Wang J, Tang C, Honig B, Murray D. 2005. Retroviral matrix domains share electrostatic homology:models for membrane binding function throughout the viral life cycle. Structure 13:1521-1531.
2. van Meer G, Voelker DR, Feigenson GW. 2008. Membrane lipids:where they are and how they behave. Nat. Rev. Mol. Cell Biol. 9:112-124.
3. Resh MD. 1999. Fatty acylation of proteins:new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta 1451:1-16.
4. Prchal J, Srb P, Hunter E, Ruml T, Hrabal R. 2012. The structure of myristoylated Mason-Pfizer monkey virus matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in its membrane binding. J. Mol. Biol. 423:427-438.
5. Fernandes F, Chen K, Ehrlich LS, Jin J, Chen MH, Medina GN, Symons M, Montelaro R, Donaldson J, Tjandra N, Carter CA. 2011. Phosphoinositides direct equine infectious anemia virus Gag trafficking and release. Traffic 12:438-451.
6. Saad J, Ablan S, Ghanam R, Kim A, Andrews K, Nagashima K, Soheilian F, Freed E, Summers M. 2008. Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-( 4,5)-bisphosphate in membrane targeting. J. Mol. Biol. 382:434-447.
7. Saad J, Miller J, Tai J, Kim A, Ghanam R, Summers M. 2006. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl. Acad. Sci. U.S.A. 103:11364-11369.
8. Chan J, Dick RA, Vogt VM. 2011. Rous sarcoma virus Gag has no specific requirement for phosphatidylinositol-(4,5)-bisphosphate for plasma membrane association in vivo or for liposome interaction in vitro. J. Virol. 85:10851-10860.
9. Chukkapalli V, Hogue IB, Boyko V, Hu WS, Ono A. 2008. Interaction between the human immunodeficiency virus type 1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient Gag membrane binding. J. Virol. 82:2405-2417.
10. Hamard-Peron E, Juillard F, Saad J, Roy C, Roingeard P, Summers M, Darlix J, Picart C, Muriaux D. 2010. Targeting of murine leukemia virus Gag to the plasma membrane is mediated by PI(4,5)P2/PS and a polybasic region in the matrix. J. Virol. 84:503-515.
11. Inlora J, Chukkapalli V, Derse D, Ono A. 2011. Gag localization and virus-like particle release mediated by the matrix domain of human Tlymphotropic virus type-1 Gag are less dependent on phosphatidylinositol-( 4,5)-bisphosphate than those mediated by the matrix domain of human immunodeficiency virus type-1 Gag. J. Virol. 85:3802-3810.
12. Ono A, Ablan S, Lockett S, Nagashima K, Freed E. 2004. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl. Acad. Sci. U.S.A. 101:14889-14894.
13. Nadaraia-Hoke S, Bann DV, Lochmann TL, Gudleski-O'Regan N, Parent LJ. 2013. Alterations in the MA and NC domains modulate phosphoinositide-dependent plasma membrane localization of the Rous sarcoma virus Gag protein. J. Virol. 87:3609-3615.
14. Chukkapalli V, Oh SJ, Ono A. 2010. Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. Proc. Natl. Acad. Sci. U.S.A. 107:1600-1605.
15. Dick RA, Goh SL, Feigenson GW, Vogt VM. 2012. HIV-1 Gag protein can sense the cholesterol and acyl chain environment in model membranes. Proc. Natl. Acad. Sci. U.S.A. 109:18761-18766.
16. Freed EO. 2006. HIV-1 Gag:flipped out for PI(4,5)P(2). Proc. Natl. Acad. Sci. U.S.A. 103:11101-11102.
17. Vlach J, Saad JS. 2013. Trio engagement via plasma membrane phospholipids and the myristoyl moiety governs HIV-1 matrix binding to bilayers. Proc. Natl. Acad. Sci. U.S.A. 110:3525-3530.
18. Briggs JA, Riches JD, Glass B, Bartonova V, Zanetti G, Krausslich HG. 2009. Structure and assembly of immature HIV. Proc. Natl. Acad. Sci. U.S.A. 106:11090-11095.
19. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, Sundquist WI, Jensen GJ. 2007. Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells. EMBO J. 26:2218-2226.
20. Demirov DG, Freed EO. 2004. Retrovirus budding. Virus Res. 106:87-102.
21. Keller PW, Johnson MC, Vogt VM. 2008. Mutations in the spacer peptide and adjoining sequences in Rous sarcoma virus Gag lead to tubular budding. J. Virol. 82:6788-6797.
22. Krausslich HG, Facke M, Heuser AM, Konvalinka J, Zentgraf H. 1995. The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J. Virol. 69:3407-3419.
23. Phillips JM, Murray PS, Murray D, Vogt VM. 2008. A molecular switch required for retrovirus assembly participates in the hexagonal immature lattice. EMBO J. 27:1411-1420.
24. Bharat TA, Davey NE, Ulbrich P, Riches JD, de Marco A, Rumlova M, Sachse C, Ruml T, Briggs JA. 2012. Structure of the immature retroviral capsid at 8 Å resolution by cryo-electron microscopy. Nature 487:385-389.
25. Ma YM, Vogt VM. 2004. Nucleic acid binding-induced Gag dimerization in the assembly of Rous sarcoma virus particles in vitro. J. Virol. 78:52-60.
26. Ma YM, Vogt VM. 2002. Rous sarcoma virus Gag protein-oligonucleotide interaction suggests a critical role for protein dimer formation in assembly. J. Virol. 76:5452-5462.
27. Yu F, Joshi SM, Ma YM, Kingston RL, Simon MN, Vogt VM. 2001. Characterization of Rous sarcoma virus Gag particles assembled in vitro. J. Virol. 75:2753-2764.
28. Accola MA, Strack B, Gottlinger HG. 2000. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 74:5395-5402.
29. Alfadhli A, Dhenub TC, Still A, Barklis E. 2005. Analysis of human immunodeficiency virus type 1 Gag dimerization-induced assembly. J. Virol. 79:14498-14506.
30. Crist RM, Datta SA, Stephen AG, Soheilian F, Mirro J, Fisher RJ, Nagashima K, Rein A. 2009. Assembly properties of human immunodeficiency virus type 1 Gag-leucine zipper chimeras:implications for retrovirus assembly. J. Virol. 83:2216-2225.
31. Johnson MC, Scobie HM, Ma YM, Vogt VM. 2002. Nucleic acidindependent retrovirus assembly can be driven by dimerization. J. Virol. 76:11177-11185.
32. Zhang Y, Qian H, Love Z, Barklis E. 1998. Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J. Virol. 72:1782-1789.
33. Campbell S, Fisher R, Towler E, Fox S, Issaq H, Wolfe T, Phillips L, Rein A. 2001. Modulation of HIV-like particle assembly in vitro by inositol phosphates. Proc. Natl. Acad. Sci. U.S.A. 98:10875-10879.
34. Campbell S, Rein A. 1999. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J. Virol. 73:2270-2279.
35. Campbell S, Vogt VM. 1997. In vitro assembly of virus-like particles with Rous sarcoma virus Gag deletion mutants:identification of the p10 domain as a morphological determinant in the formation of spherical particles. J. Virol. 71:4425-4435.
36. Gross I, Hohenberg H, Krausslich HG. 1997. In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. Eur. J. Biochem. 249:592-600.
37. Perez-Caballero D, Hatziioannou T, Martin-Serrano J, Bieniasz PD. 2004. Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on Gag precursor-membrane interactions. J. Virol. 78:9560-9563.
38. Chen BK, Rousso I, Shim S, Kim PS. 2001. Efficient assembly of an HIV-1/MLV Gag-chimeric virus in murine cells. Proc. Natl. Acad. Sci. U.S.A. 98:15239-15244.
39. Parent LJ, Wilson CB, Resh MD, Wills JW. 1996. Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J. Virol. 70:1016-1026.
40. Reed M, Mariani R, Sheppard L, Pekrun K, Landau NR, Soong NW. 2002. Chimeric human immunodeficiency virus type 1 containing murine leukemia virus matrix assembles in murine cells. J. Virol. 76:436-443.
41. Jouvenet N, Neil SJ, Bess C, Johnson MC, Virgen CA, Simon SM, Bieniasz PD. 2006. Plasma membrane is the site of productive HIV-1 particle assembly. PLoS Biol. 4:e435. doi:10.1371/journal.pbio.0040435.
42. Urano E, Aoki T, Futahashi Y, Murakami T, Morikawa Y, Yamamoto N, Komano J. 2008. Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J. Gen. Virol. 89:3144-3149.
43. Borsetti A, Ohagen A, Gottlinger HG. 1998. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J. Virol. 72:9313-9317.
44. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG. 1998. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J. 17:2699-2708.
45. O'Carroll IP, Soheilian F, Kamata A, Nagashima K, Rein A. 2013. Elements in HIV-1 Gag contributing to virus particle assembly. Virus Res. 171:341-345.
46. Gudleski N, Flanagan JM, Ryan EP, Bewley MC, Parent LJ. 2010. Directionality of nucleocytoplasmic transport of the retroviral Gag protein depends on sequential binding of karyopherins and viral RNA. Proc. Natl. Acad. Sci. U.S.A. 107:9358-9363.
47. Hearps AC, Wagstaff KM, Piller SC, Jans DA. 2008. The N-terminal basic domain of the HIV-1 matrix protein does not contain a conventional nuclear localization sequence but is required forDNAbinding and protein self-association. Biochemistry 47:2199-2210.
48. Lochrie MA, Waugh S, Pratt DG, Jr, Clever J, Parslow TG, Polisky B. 1997. In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 Gag polyprotein. Nucleic Acids Res. 25:2902-2910.
49. Parent LJ, Cairns TM, Albert JA, Wilson CB, Wills JW, Craven RC. 2000. RNA dimerization defect in a Rous sarcoma virus matrix mutant. J. Virol. 74:164-172.
50. Purohit P, Dupont S, Stevenson M, Green MR. 2001. Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection. RNA 7:576-584.
51. Ramalingam D, Duclair S, Datta SA, Ellington A, Rein A, Prasad VR. 2011. RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J. Virol. 85:305-314.
52. Steeg CM, Vogt VM. 1990. RNA-binding properties of the matrix protein (p19gag) of avian sarcoma and leukemia viruses. J. Virol. 64:847-855.
53. Dalton A, Murray P, Murray D, Vogt V. 2005. Biochemical characterization of Rous sarcoma virus MA protein interaction with membranes. J. Virol. 79:6227-6238.
54. Dalton AK, Ako-Adjei D, Murray PS, Murray D, Vogt VM. 2007. Electrostatic interactions drive membrane association of the human immunodeficiency virus type 1 Gag MA domain. J. Virol. 81:6434-6445.
55. Pornillos O, Ganser-Pornillos BK, Kelly BN, Hua Y, Whitby FG, Stout CD, Sundquist WI, Hill CP, Yeager M. 2009. X-ray structures of the hexameric building block of the HIV capsid. Cell 137:1282-1292.
56. Tang C, Loeliger E, Luncsford P, Kinde I, Beckett D, Summers MF. 2004. Entropic switch regulates myristate exposure in the HIV-1 matrix protein. Proc. Natl. Acad. Sci. U.S.A. 101:517-522.
57. Callahan E, Wills J. 2000. Repositioning basic residues in the M domain of the Rous sarcoma virus Gag protein. J. Virol. 74:11222-11229.
58. Buboltz JT, Feigenson GW. 1999. A novel strategy for the preparation of liposomes:rapid solvent exchange. Biochim. Biophys. Acta 1417:232-245.
59. Zhao J, Wu J, Heberle FA, Mills TT, Klawitter P, Huang G, Costanza G, Feigenson GW. 2007. Phase studies of model biomembranes:complex behavior of DSPC/DOPC/cholesterol. Biochim. Biophys. Acta 1768:2764-2776.
60. Kay JE. 1996. Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem. J. 314(Part 2):361-385.
61. Rollins CT, Rivera VM, Woolfson DN, Keenan T, Hatada M, Adams SE, Andrade LJ, Yaeger D, van Schravendijk MR, Holt DA, Gilman M, Clackson T. 2000. A ligand-reversible dimerization system for controlling protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 97:7096-7101.
62. Schreiber SL. 1991. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-287.
63. Kerfeld CA, Sawaya MR, Tanaka S, Nguyen CV, Phillips M, Beeby M, Yeates TO. 2005. Protein structures forming the shell of primitive bacterial organelles. Science 309:936-938.
64. Ding L, Derdowski A, Wang JJ, Spearman P. 2003. Independent segregation of human immunodeficiency virus type 1 Gag protein complexes and lipid rafts. J. Virol. 77:1916-1926.
65. Ono A, Demirov D, Freed EO. 2000. Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J. Virol. 74:5142-5150.
66. Ono A, Freed EO. 1999. Binding of human immunodeficiency virus type 1 Gag to membrane:role of the matrix amino terminus. J. Virol. 73:4136-4144.
67. Spearman P, Horton R, Ratner L, Kuli-Zade I. 1997. Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J. Virol. 71:6582-6592.
68. Zhou W, Resh MD. 1996. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J. Virol. 70:8540-8548.
69. Scheifele LZ, Garbitt RA, Rhoads JD, Parent LJ. 2002. Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein. Proc. Natl. Acad. Sci. U.S.A. 99:3944-3949.
70. Butterfield-Gerson KL, Scheifele LZ, Ryan EP, Hopper AK, Parent LJ. 2006. Importin-beta family members mediate alpharetrovirus Gag nuclear entry via interactions with matrix and nucleocapsid. J. Virol. 80:1798-1806.
71. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK, Wang H, McCutcheon JP, Sundquist WI, Hill CP. 1997. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278:849-853.
72. del Alamo M, Neira JL, Mateu MG. 2003. Thermodynamic dissection of a low affinity protein-protein interface involved in human immunodeficiency virus assembly. J. Biol. Chem. 278:27923-27929.
73. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. 1993. Controlling signal transduction with synthetic ligands. Science 262:1019-1024.
74. Alfadhli A, Still A, Barklis E. 2009. Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids. J. Virol. 83:12196-12203.
75. Callahan E, Wills J. 2003. Link between genome packaging and rate of budding for Rous sarcoma virus. J. Virol. 77:9388-9398.
76. Jones CP, Datta SA, Rein A, Rouzina I, Musier-Forsyth K. 2011. Matrix domain modulates HIV-1 Gag's nucleic acid chaperone activity via inositol phosphate binding. J. Virol. 85:1594-1603.
77. Morikawa Y, Zhang WH, Hockley DJ, Nermut MV, Jones IM. 1998. Detection of a trimeric human immunodeficiency virus type 1 Gag intermediate is dependent on sequences in the matrix protein, p17. J. Virol. 72:7659-7663.
78. Hill CP, Worthylake D, Bancroft DP, Christensen AM, Sundquist WI. 1996. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein:implications for membrane association and assembly. Proc. Natl. Acad. Sci. U.S.A. 93:3099-3104.
79. Datta SA, Zhao Z, Clark PK, Tarasov S, Alexandratos JN, Campbell SJ, Kvaratskhelia M, Lebowitz J, Rein A. 2007. Interactions between HIV-1 Gag molecules in solution:an inositol phosphate-mediated switch. J. Mol. Biol. 365:799-811.
80. Datta SA, Curtis JE, Ratcliff W, Clark PK, Crist RM, Lebowitz J, Krueger S, Rein A. 2007. Conformation of the HIV-1 Gag protein in solution. J. Mol. Biol. 365:812-824.
81. Datta SA, Heinrich F, Raghunandan S, Krueger S, Curtis JE, Rein A, Nanda H. 2011. HIV-1 Gag extension:conformational changes require simultaneous interaction with membrane and nucleic acid. J. Mol. Biol. 406:205-214.
82. Spearman P, Ratner L. 1996. Human immunodeficiency virus type 1 capsid formation in reticulocyte lysates. J. Virol. 70:8187-8194.
83. Chukkapalli V, Inlora J, Todd GC, Ono A. 2013. Evidence in support of RNA-mediated inhibition of phosphatidylserine-dependent HIV-1 Gag membrane binding in cells. J. Virol. 87:7155-7159.
84. Alfadhli A, McNett H, Tsagli S, Bachinger HP, Peyton DH, Barklis E. 2011. HIV-1 matrix protein binding to RNA. J. Mol. Biol. 410:653-666.
85. Dooher JE, Schneider BL, Reed JC, Lingappa JR. 2007. Host ABCE1 is at plasma membrane HIV assembly sites and its dissociation from Gag is linked to subsequent events of virus production. Traffic 8:195-211.
86. Klein KC, Reed JC, Tanaka M, Nguyen VT, Giri S, Lingappa JR. 2011. HIV Gag-leucine zipper chimeras form ABCE1-containing intermediates and RNase-resistant immature capsids similar to those formed by wildtype HIV-1 Gag. J. Virol. 85:7419-7435.
87. Dong X, Li H, Derdowski A, Ding L, Burnett A, Chen X, Peters TR, Dermody TS, Woodruff E, Wang JJ, Spearman P. 2005. AP-3 directs the intracellular trafficking of HIV-1 Gag and plays a key role in particle assembly. Cell 120:663-674.
88. Larson DR, Ma YM, Vogt VM, Webb WW. 2003. Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy. J. Cell Biol. 162:1233-1244.
89. Kutluay SB, Bieniasz PD. 2010. Analysis of the initiating events in HIV-1 particle assembly and genome packaging. PLoS Pathog. 6:e1001200. doi:10.1371/journal.ppat.1001200.
90. Fogarty KH, Chen Y, Grigsby IF, Macdonald PJ, Smith EM, Johnson JL, Rawson JM, Mansky LM, Mueller JD. 2011. Characterization of cytoplasmic Gag-Gag interactions by dual-color z-scan fluorescence fluctuation spectroscopy. Biophys. J. 100:1587-1595.
91. Fogarty KH, Zhang W, Grigsby IF, Johnson JL, Chen Y, Mueller JD, Mansky LM. 2011. New insights into HTLV-1 particle structure, assembly, and Gag-Gag interactions in living cells. Viruses 3:770-793.
92. Grigsby IF, Zhang W, Johnson JL, Fogarty KH, Chen Y, Rawson JM, Crosby AJ, Mueller JD, Mansky LM. 2010. Biophysical analysis of HTLV-1 particles reveals novel insights into particle morphology and Gag stochiometry. Retrovirology 7:75. doi:10.1186/1742-4690-7-75.